MRKR · NASDAQ
Marker Therapeutics (MRKR) Stock Price & Fundamentals
Marker Therapeutics (MRKR) closed at $869.36 on Oct 9, 2026, down 0.44% from the previous close of $873.23.
Share price, past year
1Y +13.64%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $869.36 |
| Sep 30, 2026 | $869.27 |
| Aug 31, 2026 | $932.19 |
| Jul 31, 2026 | $865.56 |
| Jun 30, 2026 | $897.47 |
| May 29, 2026 | $923.77 |
| Apr 30, 2026 | $878.96 |
| Mar 31, 2026 | $889.19 |
| Feb 27, 2026 | $803.81 |
| Jan 30, 2026 | $777.20 |
| Dec 31, 2025 | $758.03 |
| Nov 28, 2025 | $707.77 |
| Oct 31, 2025 | $743.54 |
Key statistics
- Market cap
- $14.52B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.35
- Revenue (TTM)
- $3.95M
- Net income (TTM)
- −$8.71M
- Shares outstanding
- 16.7M
- Dividend yield
- —
- 52-week range
- $698.31 – $940.47
Marker Therapeutics's market cap is $14.52B, based on a share price of $869.36 and 16.7M shares outstanding as of Jun 30, 2026.
Financials
Marker Therapeutics reported revenue of $3.55M for fiscal 2025, down 46.19% from fiscal 2024.
Marker Therapeutics reported a net loss of $12.16M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.55M | −46.2% | −$12.16M | −343.0% | −$0.79 | — |
| FY2024ended Dec 31, 2024 | $6.59M | +99.1% | −$10.73M | −162.8% | −$1.19 | — |
| FY2023ended Dec 31, 2023 | $3.31M | −5.8% | −$8.24M | −248.8% | −$0.94 | — |
| FY2022ended Dec 31, 2022 | $3.51M | — | −$29.93M | −851.9% | −$3.58 | — |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$41.88M | — | −$5.47 | — |
| FY2020ended Dec 31, 2020 | $500.00K | +134.5% | −$28.71M | −5,741.2% | −$0.61 | — |
| FY2019ended Dec 31, 2019 | $213.19K | +3.5% | −$21.43M | −10,050.9% | −$0.47 | −$18.66M |
| FY2018ended Dec 31, 2018 | $205.99K | +12.5% | −$147.96M | −71,826.3% | −$7.75 | −$14.63M |
| FY2017ended Dec 31, 2017 | $183.06K | — | −$10.98M | −5,999.1% | −$1.16 | −$8.44M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $751.69K | −$3.18M | −$0.16 |
| Q4 FY2025ended Dec 31, 2025 | $1.10M | −$1.70M | $0.02 |
| Q3 FY2025ended Sep 30, 2025 | $1.23M | −$2.00M | −$0.12 |
| Q2 FY2025ended Jun 30, 2025 | $861.18K | −$4.02M | −$0.29 |
| Q1 FY2025ended Mar 31, 2025 | $349.10K | −$4.45M | −$0.40 |
| Q4 FY2024ended Dec 31, 2024 | $2.25M | −$3.84M | −$0.41 |
| Q3 FY2024ended Sep 30, 2024 | $1.93M | −$2.31M | −$0.26 |
| Q2 FY2024ended Jun 30, 2024 | $1.17M | — | — |
Company profile
- Name
- Marker Therapeutics, Inc.
- Ticker
- MRKR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2450 Holcombe Blvd, Tmc Partners Office 1.311, Houston, TX 77021
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001094038
Recent SEC filings
- Aug 14, 2026
- May 15, 2026
- May 4, 2026
- Mar 19, 2026
- Mar 18, 2026
- Feb 9, 2026
- Nov 14, 2025
- Nov 13, 2025
Frequently asked questions
What is Marker Therapeutics's stock price?
Marker Therapeutics (MRKR) closed at $869.36 on Oct 9, 2026, down 0.44% from the previous close of $873.23.
What is Marker Therapeutics's market cap?
Marker Therapeutics's market cap is $14.52B, based on a share price of $869.36 and 16.7M shares outstanding as of Jun 30, 2026.
How much revenue does Marker Therapeutics make?
Marker Therapeutics reported revenue of $3.55M for fiscal 2025, down 46.19% from fiscal 2024.
Does Marker Therapeutics pay a dividend?
Marker Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Marker Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures